Pfizer
Fei Jie is a seasoned biostatistics professional with extensive experience in the pharmaceutical industry. Currently serving as Senior Director of Biostatistics at Pfizer since December 2023, Fei Jie leads a team in statistical initiatives. Previously, as Senior Director at Seagen from January 2022 to December 2023, Fei Jie was the global statistical lead for Adcetris, contributing to its approval for pediatric patients with untreated high-risk classical Hodgkin lymphoma. Fei Jie also held the position of Director of Biostatistics at Daiichi Sankyo, overseeing statistical support for Enhertu in breast cancer, and has significant experience with Astellas Pharma as Biostatistics Director, focusing on solid tumors and hematological malignancies. Earlier experience includes working as a Statistician at AbbVie in late-stage oncology development. Fei Jie holds a Ph.D. in Biostatistics from the University of Illinois Chicago and a Ph.D. in Immunology from Iowa State University.
This person is not in any teams
This person is not in any offices
Pfizer
616 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.